Influenza Hemagglutination-inhibition Antibody Titer as a Mediator of Vaccine-induced Protection for Influenza B

Clinical Infectious Diseases

Volumn 68, Issue 10, 2019, Pages 1713-1717

  Cowling, Benjamin J ^a   Lim, Wey Wen ^a   Perera, Ranawaka A P M ^a   Fang, Vicky J ^a   Leung, Gabriel M ^a   Malik Peiris, J S ^a   Tchetgen Tchetgen, Eric J ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Correlate of protection; Hemagglutination inhibition; Influenza; Vaccination

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; PLACEBO; INACTIVATED VACCINE; VACCINE; VIRUS ANTIBODY;

ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; ERYTHROCYTE; HUMAN; IMMUNE RESPONSE; INFLUENZA B; INFLUENZA VACCINATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; BLOOD; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA; INFLUENZA B VIRUS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADOLESCENT; ANTIBODIES, VIRAL; CHILD; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINE POTENCY; VACCINES, INACTIVATED;

EID: 85064250892     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciy759     Document Type: Article

References (17)

1. Palache A, Abelin A, Hollingsworth R, et al. Survey of distribution of seasonal influenza vaccine doses in 201 countries (2004-2015): the 2003 World Health Assembly resolution on seasonal influenza vaccination coverage and the 2009 influenza pandemic have had very little impact on improving influenza control and pandemic preparedness. Vaccine 2017; 35:4681-6.
2. Talbot HK, Nian H, Zhu Y, Chen Q, Williams JV, Griffin MR. Clinical effectiveness of split-virion versus subunit trivalent influenza vaccines in older adults. Clin Infect Dis 2015; 60:1170-5.
3. Beyer WE, Palache AM, Osterhaus AD. Comparison of serology and reac-togenicity between influenza subunit vaccines and whole virus or split vaccines: a review and meta-analysis of the literature. Clin Drug Investig 1998; 15:1-12.
4. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglu-tination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. Journal of Hygiene 1972; 70:767-77.
5. Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 2012; 54:1615-7.
6. Trombetta CM, Montomoli E. Influenza immunology evaluation and correlates of protection: a focus on vaccines. Expert Rev Vaccines 2016; 15:967-76.
7. McElhaney JE, Xie D, Hager WD, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006; 176:6333-9.
8. Nguyen QC, Osypuk TL, Schmidt NM, Glymour MM, Tchetgen Tchetgen EJ. Practical guidance for conducting mediation analysis with multiple mediators using inverse odds ratio weighting. Am J Epidemiol 2015; 181:349-56.
9. Cowling BJ, Ng S, Ma ES, et al. Protective efficacy against pandemic influenza of seasonal influenza vaccination in children in Hong Kong: a randomized controlled trial. Clin Infect Dis 2012; 55:695-702.
10. Cowling BJ, Chan KH, Fang VJ, et al. Comparative epidemiology of pandemic and seasonal influenza A in households. N Engl J Med 2010; 362:2175-84.
11. Cowling BJ, Ng S, Ma ES, et al. Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong. Clin Infect Dis 2010; 51:1370-9.
12. Cowling BJ, Lim WW, Perera RAPM, et al. Data from: Influenza hemagglutination-inhibition antibody titer as a mediator of vaccine-induced protection for influenza B. Available at: https://datadryad.org/resource/doi:10.5061/dryad.cv37539. Accessed 26 September 2018.
13. Dunning AJ, Diaz Granados CA, Voloshen T, Hu B, Landolfi VA, Talbot HK. Correlates of protection against influenza in the elderly: results from an influenza vaccine efficacy trial. Clin Vaccine Immunol 2016; 23:228-35.
14. Tanimoto T, Nakatsu R, Fuke I, et al. Estimation of the neuraminidase content of influenza viruses and split-product vaccines by immunochromatography. Vaccine 2005; 23:4598-609.
15. Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis 2016; 16:942-51.
16. Ng S, Fang VJ, Ip DK, et al. Estimation of the association between antibody titers and protection against confirmed influenza virus infection in children. J Infect Dis 2013; 208:1320-4.
17. Zhao X, Fang VJ, Ohmit SE, Monto AS, Cook AR, Cowling BJ. Quantifying protection against influenza virus infection measured by hemagglutination-inhibition assays in vaccine trials. Epidemiology 2016; 27:143-51.